Inhibikase Therapeutics, Inc. (IKT) Misses Q2 EPS by 30c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) reported Q2 EPS of ($1.11), $0.30 worse than the analyst estimate of ($0.81).
For earnings history and earnings-related data on Inhibikase Therapeutics, Inc. (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Mannatech (MTEX) Tops Q2 EPS by 53c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
